Skip to main content
PMC home page
Journal of Cell Communication and Signaling logoLink to Journal of Cell Communication and Signaling
. 2021 Oct 29;16(2):301–310. doi: 10.1007/s12079-021-00652-0

A modular map of Bradykinin-mediated inflammatory signaling network

D A B Rex 1, K Deepak 1, Neelanchal Vaid 1, Shobha Dagamajalu 1,✉, Richard Kumaran Kandasamy 2,3, Trude Helen Flo 2, T S Keshava Prasad 1,✉
PMCID: PMC8554507  PMID: 34714516

Abstract

Bradykinin, a member of the kallikrein-kinin system (KKS), is associated with an inflammatory response pathway with diverse vascular permeability functions, including thrombosis and blood coagulation. In majority, bradykinin signals through Bradykinin Receptor B2 (B2R). B2R is a G protein-coupled receptor (GPCR) coupled to G protein family such as Gαqs, Gαq/Gα11, Gαi1, and Gβ1γ2. B2R stimulation leads to the activation of a signaling cascade of downstream molecules such as phospholipases, protein kinase C, Ras/Raf-1/MAPK, and PI3K/AKT and secondary messengers such as inositol-1,4,5-trisphosphate, diacylglycerol and Ca2+ ions. These secondary messengers modulate the production of nitric oxide or prostaglandins. Bradykinin-mediated signaling is implicated in inflammation, chronic pain, vasculopathy, neuropathy, obesity, diabetes, and cancer. Despite the biomedical importance of bradykinin, a resource of bradykinin-mediated signaling pathway is currently not available. Here, we developed a pathway resource of signaling events mediated by bradykinin. By employing data mining strategies in the published literature, we describe an integrated pathway reaction map of bradykinin consisting of 233 reactions. Bradykinin signaling pathway events included 25 enzyme catalysis reactions, 12 translocations, 83 activation/inhibition reactions, 11 molecular associations, 45 protein expression and 57 gene regulation events. The pathway map is made publicly available on the WikiPathways Database with the ID URL: https://www.wikipathways.org/index.php/Pathway:WP5132. The bradykinin-mediated signaling pathway map will facilitate the identification of novel candidates as therapeutic targets for diseases associated with dysregulated bradykinin signaling.

Supplementary Information

The online version contains supplementary material available at 10.1007/s12079-021-00652-0.

Keywords: Bradykinin storm, Post-translational modifications, Protein–protein interactions, Signaling pathways

Introduction

Bradykinin is a potent, short-lived vasoactive peptide, which acts as an inflammatory mediator. It is a constituent of the kallikrein-kinin system (KKS). Kinins are released from high molecular weight kininogens (HMWK) and low molecular weight kininogens (LMWK) by the action of plasma kallikrein (PK) or tissue kallikrein (TK). HMWK and LMWK are the two components of KKS and play a major role in the synthesis of bradykinin (Leeb-Lundberg et al. 2005; Vandell et al. 2008; Hofman et al. 2016a, b; Nokkari et al. 2018). The LMWK is cleaved by tissue kallikrein into a 10-amino-acid peptide, lysyl-bradykinin (kallidin), with a sequence Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (Kaplan et al. 2002). The action of a plasma amino-peptidase on kallidin cleaves the N-terminal Lys and liberates bradykinin as a 9-amino-acid peptide. The other arm of the cascade comprises factor XII, an initiating protein that binds to charged surface macromolecules and forms factor XIIa, which converts prekallikrein into active plasma kallikrein. Further, HMWK is cleaved by plasma kallikrein into nonapeptide bradykinin (Kaplan et al. 2002; Kenniston et al. 2014). Degradation of bradykinin occurs by the action of kininase I and kininase II enzymes. Kininase I, also known as plasma carboxypeptidase, removes the C- terminal Arg from bradykinin and kallidin to form Des-Arg9-bradykinin and Des-Arg10-kallidin, respectively. Kininase II is similar to angiotensin-converting enzyme (ACE) in function and metabolizes bradykinin into two C- terminal dipeptides and a heptapeptide (Kaplan et al. 2002).

Bradykinin is released in pathological conditions such as trauma and inflammation, which binds to its kinin receptors. It is encoded by exon 10 of the kininogen gene located on chromosome 3 (3q26) in humans (Fong et al. 1991). Bradykinin activates several second messenger systems, thereby regulating blood–brain barrier permeability, blood pressure, pain perception, glutamate release from astrocytes, neuronal differentiation, and nitric oxide production (Whalley et al. 2012).

The action of bradykinin is mediated through an interaction with cell surface bradykinin receptors. Bradykinin Receptor B1 (B1R) and Bradykinin Receptor B2 (B2R) are the two subtypes of bradykinin receptors, which belong to the GPCR family (Leeb-Lundberg et al. 2005; Marceau et al. 2020). B1R encoded by the gene BDKRB1 has minimal expression in healthy tissues, and its expression is induced only under special conditions such as injury and inflammation (Couture et al. 2001; Qadri and Bader 2018). In most cases, bradykinin acts through the B2R, which is encoded by the gene BDKRB2. B2R is ubiquitously expressed and implicated in vasodilation, osmoregulation, smooth muscle contraction, and nociceptors' activation (Leeb-Lundberg et al. 2005). B2R expression upregulated under pathological conditions of tissue injury due to oxidative stress, pro-inflammatory stimuli such as exposure to lipopolysaccharides, endotoxins, cytokines (IL-1beta and TNF-alpha) and vasoactive peptide stimuli as it is seen in the renin-angiotensin system (RAS) (Marceau et al. 2002; Tschope et al. 2002; Bossi et al. 2009; Jaffa et al. 2012; Naffah-Mazzacoratti Mda et al. 2014).

Bradykinin stimulates B2R coupled with G proteins and activates signaling molecules such as protein kinase C (PKC), phospholipase C (PLC), mitogen-activated protein kinases (MAPKs), phosphoinositide-3 kinase (PI3K)/AKT and second messengers IP3 (inositol triphosphate), diacylglycerol (DAG) and Ca2+ ions (Kakoki and Smithies 2009; Dong et al. 2015; Wang et al. 2017). These second messengers mediate signaling mechanisms (e.g., nitric oxide or prostaglandin production) (Kakoki and Smithies 2009). Besides, bradykinin is also known to be involved in the activation of inflammatory cytokines. Previous studies have demonstrated that bradykinin-induced activation of MAPKs is involved in the upregulation of several cytokines such as IL-6, IL-1β, IL-8 and IL-2 (Paegelow et al. 1995; Pan et al. 1996; Huang et al. 2003; Meini et al. 2011; Yang et al. 2018) which are implicated in inflammation, respiratory, gastrointestinal, cardiac, neuronal, ophthalmologic and dermatological problems. Recent reports have shown that bradykinin storm may be responsible for the more severe symptoms of Coronavirus disease (COVID-19) (Garvin et al. 2020; Roche and Roche 2020; Wilczynski et al. 2021). Some reports suggest that B2R forms a complex with ACE, and this is thought to play a role in cross-talk between the RAS and the KKS (da Costa et al. 2014). Accumulation of bradykinin is implicated in angioedema by genetic defects and ACE inhibitors (Bas et al. 2007). Besides, bradykinin also plays a major role in cancer progression mechanisms (Stewart et al. 2002), for instance, with increased lung cancer risks (Kmietowicz 2018) and proliferation and migration in gastric cancers (Wang et al. 2017), in addition to allergic rhinitis, asthma, and anaphylaxis (Kaplan et al. 2002).

Recent computational analyses suggested that genes related to the bradykinin were up-regulated in bronchoalveolar lavage (BAL) samples of COVID-19 patients. The system implicates the core of the mechanisms triggering the adverse array of symptoms such as muscle pain, fatigue, nausea, vomiting, diarrhoea, headaches, and reduced cognitive function (Garvin et al. 2020). Recent reports show that SARS-CoV-2 employs its spike protein (S) antigen to interact with ACE2 and invade target cells (Astuti and Ysrafil 2020; Zhang et al. 2020). The loss of ACE2 activity and subsequent rise in Angiotensin-II leads to a fall in ACE function through a negative feedback loop, ultimately resulting in raised bradykinin levels (Zhu et al. 2010). The increase of bradykinin may be due to the increases in the density of mast cells in the lungs of COVID-19 patients (Motta Junior et al. 2020). Even though several studies have been conducted at the molecular level to deduce the bradykinin signaling pathways, an organized network of molecular reactions induced by bradykinin is not publicly available. Therefore, we curated bradykinin-induced reactions from the literature and organized them into a dataset of molecular reactions. We developed a resource of signaling events mediated by bradykinin, similar to the previously published signaling pathways of IL-18, IL-10, IL-33, endothelin, oncostatin M and AXL, available in the NetPath and Wikipathways database (Dey et al. 2013; Soman et al. 2013; Verma et al. 2016; Pinto et al. 2018; Rex et al. 2020; Dagamajalu et al. 2021a, 2021b).

Methodology

We carried out a literature survey of articles related to bradykinin-mediated signaling. The articles were fetched from PubMed using query terms ("Bradykinin" OR "BK" OR "BK receptor" OR "B1receptor" OR "BK receptor B1" OR "BDKRB1" OR "B1R" OR"B2 receptor" OR "BK receptor B2" OR "BDKRB2" OR "B2R") AND ("pathway" OR "signaling" OR "signalling" OR "induced pathway" OR "induced signaling" OR "induced signalling"). The research articles were screened manually to evaluate the presence of bradykinin-induced signaling events. The systematic manual curation of signaling events was done based on the previously described PathBuilder tool, NetSlim and NetPath annotation criteria (Kandasamy et al. 2009, 2010; Raju et al. 2011). Accordingly, molecular events induced or influenced by bradykinin were included in the pathway. Further, curated downstream molecules were categorized into activation/inhibition, post-translational modifications (PTMs), translocation, molecular association, gene regulation and protein expression events. Additionally, information about cell lines used in the experiment, type of experiment, gene and protein regulation type (upregulation/downregulation) and PTMs (site and residue wherever available) were also curated. The curated information was further subjected to quality control through an internal review by a couple of experienced curators. Each described signaling event in the pathway was hyperlinked to the abstracts of corresponding articles from where it was retrieved.

PathVisio software used to depict pathway map of bradykinin mediated molecular signaling events (Kutmon et al. 2015).

Results

In the current study, the PubMed search using query terms fetched 4444 articles related to the bradykinin signaling pathway until September 2020. These articles were carefully reviewed based on our NetPath annotation criteria and shortlisted into 400 articles. The annotated articles provided several molecular reactions such as 11 molecular interactions, 25 enzyme catalysis events, 12 translocations, 83 activation/inhibition reactions, 45 protein expressions and 57 gene regulation events (Supplementary Data S1). These events were further incorporated into the corresponding signaling pathway map (Fig. 1). Information regarding bradykinin signaling events can be obtained from the WikiPathways database (https://www.wikipathways.org/index.php/Pathway:WP5132). The signaling pathway map can be freely downloaded in png, pdf and gpml formats from this database.

Fig. 1.

Fig. 1

Open in a new tab

Schematic representation of bradykinin mediated signaling pathway. The signaling pathway map represents molecules involved in ligand-receptor interactions and bradykinin-activated downstream molecular events including molecular association, catalysis, translocation, and gene regulation events. Information regarding the post-translational modification site and the residue is also shown in the pathway.

Description of the bradykinin signaling pathway

Bradykinin, a pro-inflammatory nonapeptide, is released by the action of plasma or tissue kallikreins on kininogens (Drouin et al. 1979; Kakoki and Smithies 2009). Signaling by bradykinin is mainly mediated through B2R, a receptor of the seven-transmembrane GPCR family, which are capable of generating a broad spectrum of physiological responses such as vasodilation, fluid balance and retention, smooth muscle contraction, and algesia on target cells (Khasar et al. 1995; Virych et al. 2017). Bradykinin/B2R induces the activation of MAPK1/3 via PKC and c-Src pathways, which up-regulates matrix metalloproteinase (MMP)-9 and increases the conventional outflow facility in human trabecular meshwork cells (Webb et al. 2011). Furthermore, bradykinin enhance cell proliferation by the activation of cytosolic calcium, PKC-alpha (α), -beta (β), -delta (δ), -epsilon (ε) and -eta (η) and MAPK1/3 mediated signaling in primary culture of breast cancer cells, pheochromocytoma PC12 cells and ventricular myocytes (Clerk et al. 1996; Graness et al. 1997; Greco et al. 2005). In addition, c-Src phosphorylates FRS2 at Tyr196, leading to the activation of MAPK1/3 and nuclear translocation of STAT3, which ultimately results in the release of FGF-2 protein. The release of FGF-2 mediates various biological effects, including permeability, migration and inflammation in human HREC and HUVEC cell lines (Terzuoli et al. 2018).

Bradykinin mediates signaling modules in various cells such as cardiomyocytes, epithelial cells, fibroblasts and neuroblastoma cells. In synovial fibroblasts, bradykinin stimulates B2R and activates IKKα/β (IKK alpha/beta) via the activation of PLC, PKC-δ (PRKCD) and increases the binding of RELA and NFKB1 to the NF-κB element, which leads to the increased production of IL-6 in rheumatoid arthritis (Lee et al. 2008). In addition, B2R stimulation by bradykinin activates EGFR mediated PI3K activation and translocation of PRKCD from the cytoplasm to the plasma membrane to induce MAPK1/3 activation and FOS protein expression, which lead to cell proliferation in human breast epithelial cells (Greco et al. 2004). In human cardiac c-kit+ progenitor cells, B2R activation by bradykinin releases Ca2+ from the endoplasmic reticulum and influx through store-operated Ca2+ entry (SOCE) complex activates AKT, MAPK1/3 phosphorylation and cyclin D1 protein expression leads to cell proliferation and migration to promote myocardial repair (Li et al. 2017). In human neuroblastoma SH-SY5Y cells, bradykinin promotes neurite outgrowth through rapid transient MARCKS phosphorylation through PKC dependent RhoA/ROCK pathway followed by dephosphorylation with the help of protein phosphatase 2A (PP2A) (Tanabe et al. 2012). Bradykinin stimulates myofibroblast migration through Hsp27 phosphorylation and cyclooxygenase 2 (COX2) expression via PKD in the CCD-18Co cell line (Chu et al. 2017). In human ciliary muscle (CM) cells, bradykinin/B2R leads to expression of COX1, and COX2 via MAPK signaling pathway. Subsequent release of PGE2 and PGF2α to the extracellular space is involved in the modulation of intraocular pressure (IOP) (Sharif et al. 2013).

In addition to MAPK activation, PI3K/AKT/mTOR/GSK3β is another major signal transducer involved in bradykinin mediated signaling. In human cardiac c-Kit + progenitor cells, PLC-mediated Ca2+ influx through the SOCE channel initiates AKT phosphorylation and CCND1 expression, leading to cell cycle progression and migration (Li et al. 2018). In human retinal pigment epithelial (ARPE) cells, bradykinin stimulates PI3K/AKT pathway via B1R and B2R to activate PLA2/COX2-mediated up-regulation of SLC1A6 and SLC1A1, which triggers glutamate uptake (Lim et al. 2008). Bradykinin/B2R/PI3K/eNOS signaling exerts a potent chemoattractant activity on CD133( +) and CD34( +) circulating angiogenic progenitor cells (CPCs) associated with neovascularization potential (Krankel et al. 2008).

Bradykinin signaling pathway in diseases

Bradykinin is a potent pro-inflammatory mediator, neutrophil chemoattractant and angiogenic factor, which acts through B1R and B2R in many inflammatory diseases such as chronic pain, vasculopathy, asthma, allergic rhinitis, neuropathy, obesity, rheumatoid arthritis, diabetes, cancer and infectious disease (Barnes 1992; Couture et al. 2001; Wang et al. 2008; Dagnino et al. 2020; Lau et al. 2020). Lys-des[Arg9]-bradykinin/B1R induces the epidermal growth factor receptor (EGFR) and downstream signaling via the MAPK1/3 activation mechanism modulate neutrophils migration by upregulating MMP-2 and MMP-9 in estrogen-sensitive and -insensitive breast cancer cells (Ehrenfeld et al. 2011). B1R activation upregulates chemokine CXCL5A expression involved in neutrophil recruitment at sites of inflammation (Duchene et al. 2007).

Inflammation

Bradykinin induced pro-survival and proliferative intracellular signaling in human hepatic stellate cells and rat hepatocytes through AKT mediated NF-κB translocation and downregulation of TGFB1 and COL1A1 expression attenuate liver damage and fibrosis (Sancho-Bru et al. 2007). Further, in human airway epithelial cells, bradykinin activates the Ras/Raf-1/MAPK pathway, which in turn leads to the activation of IKKα/β and NF-κB and up-regulation of COX2, which is involved in the transition of acute allergic reactions to chronic airway inflammatory diseases, such as asthma (Chen et al. 2004).

Bradykinin triggers the activation of TRPA1 via the PLC and PKA pathways in response to tissue inflammation, which might trigger the sensation of pain in rat DRG neurons (Wang et al. 2008). Bradykinin receptors induce the overexpression of inflammatory cytokines, including TNF-α and IL-10, which are involved in inflammation in the human salivary gland cells (Lee et al. 2017). Bradykinin induces the expression of IL-8 via the binding of transcription factors AP-1, nuclear factor (NF)-IL-6 and NF-κB to the IL-8 promoter via prostaglandin E2 dependent and independent activation in human airway smooth muscle cells (Zhu et al. 2003). Recent studies have reported that bradykinin-induced COX-2 expression and PGE2 release via PKC-δ-dependent activation of MAPK1/3 and NF-κB pathways may lead to brain injury and inflammatory diseases in human CM cells, podocytes, rat astrocytes and A549 cells (Chen et al. 2004; Hsieh et al. 2007; Sharif et al. 2013; Saoud et al. 2020). In vulvar vestibule fibroblasts, bradykinin/B2R induces NF-κB activation, which increases the IL-6 release and causes pain (Falsetta et al. 2016). In human articular chondrocytes and renal epithelial cells, bradykinin induces the release of inflammatory cytokines such as IL-6 and IL-8 via NF-κB signaling mechanism (Meini et al. 2011; Yang et al. 2018).

Cancer

The bradykinin-mediated B2R triggers NF-κB activation via Gαqs, Gβ1γ2, PI3K, AKT and IKK2 pathway in HeLa cells (Xie et al. 2000). In A549 lung epithelial cells, bradykinin requires Gq/11 to activate MAPK1/3 and MAPK14, which induces the phosphorylation of EGFR at Ser 1047 and up-regulates the transcription of dual-specificity MAPK phosphatase 5 (DUSP5) (Izumi et al. 2018). Bradykinin mediated B2R activation leads to cell proliferation in human renal carcinoma A498 cells through MAPK1/3 and NHE1 pathways (Kramarenko et al. 2012). Also, bradykinin/B2R promoted the proliferation, migration, and invasion of cervical cancer cells via the STAT3 signaling pathway by upregulating the expression of MMP-2, MMP-9 and downregulating the expression pro‑apoptotic protein cleaved caspase‑9 (Yang et al. 2009; Wang et al. 2019). Bradykinin enhances cell migration in human prostate cancer cells through B2R/PKCδ/c-Src-dependent signaling by regulating the expression of MMP-9 via the NF-κB pathway (Yu et al. 2013). In head and neck squamous cell carcinomas, the bradykinin/B2R activation upregulates COX-2 through the MAPKs pathway in tumorigenesis (Zhang et al. 2008). Bradykinin promotes cell proliferation, migration, invasion, and tumor growth of gastric cancer by upregulation of MMP-2, MMP-9, COX-2 and downregulation of E-cadherin via MAPK pathway (Wang et al. 2017).

In various breast cancer cells, bradykinin-induced proliferation through PKC mediated MAPK, PI3K and AKT pathways (Greco et al. 2004, 2005, 2006). Bradykinin/B2R induced PI3K activation mediates the translocation of PRKCE from the cytosol to plasma membrane in the human colon carcinoma cell line SW-480 (Graness et al. 1998). In human prostate cancer cells, bradykinin/B2R signaling induces VEGF expression leads to angiogenesis through AKT/mTOR/NF-kB/AP-1 pathway (Yu et al. 2014). In the human colorectal cancer cell line SW480, bradykinin increases IL-6 production via B2R and the MAPK pathway, contributing to invasion and migration (Wang et al. 2014).

Other diseases

In mesangial cells, c-Src/MAPK activation by bradykinin induces CTGF, TGF-beta RII, and collagen I expression, which contributes to the development of diabetic nephropathy (Tan et al. 2005). SARS-CoV-2 infection activates inflammatory cytokine storm, which leads to multi-organ injury in the host (Rex et al. 2021). Recent studies reported that dysregulated bradykinin signaling is at the core of most of the symptoms of the SARS-CoV-2 infection. A vicious positive bradykinin feedback loop has been suspected in the progression of the cytokine storm mediated by IL-6 and IL-8 (Garvin et al. 2020; Roche and Roche 2020). The bradykinin/B2R mediated signaling induces NO production and S-nitrosylation of RAS and EGFR, which activates MAPK1/3 and up-regulates VEGF protein expression leading to angiogenesis in HUVEC cells (Moraes et al. 2014). Several studies reported that bradykinin has an important role in a broad range of human diseases. Therefore, an organized integrative pathway map of bradykinin will provide a platform for accelerating scientific investigation on the role of bradykinin in various diseases.

Drugs that target Bradykinin signaling

Bradykinin is known to play a role in certain cardiovascular conditions (Blaes and Girolami 2013). In such a state, B2R agonists or ACE inhibitors are employed to enhance bradykinin lifetime and its downstream effects (Jalowy et al. 1998; Campbell et al. 2004). However, the pathological state of chronic inflammation witnessed in Alzheimer's disease due to the elevated levels of bradykinin (Singh et al. 2020a, 2020b). Similarly, overexpression of bradykinin was observed in hereditary angioedema, asthma and COVID-19 patients (Hofman et al.2016a, 2016b; Ricciardolo et al. 2018; Garvin et al. 2020). In such conditions, bradykinin effects countered using antagonists like Hoe140, which competitively antagonizes B2R (Wirth et al. 1991). Alternatively, kallikrein inhibitors such as Lanadelumab, Garadacimab, Ecallantide (DX-88), and Berotralstat were used to interfere with PK activity, which hinder HMWK cleavage (Farkas and Varga 2011; Davoine et al. 2020; Manning and Kashkin 2021; Wedner et al. 2021; Zuraw et al. 2021). A recent study reported that a new chemical, compound 3, can antagonize B2R even at a picomolar concentration (Lesage et al. 2020).

Conclusions

Bradykinin-mediated signaling implicated in inflammation, chronic pain, vasculopathy, neuropathy, obesity, diabetes, and cancer. However, the role of the bradykinin-mediated signaling pathway in inflammatory diseases is still unclear. In-depth data mining and depiction of molecular reactions induced by bradykinin into a spatiotemporally organized signaling network will help the future biomedical investigation in bradykinin signaling. The comprehensive network map of bradykinin signaling will provide several peripheral novel proteins with undefined functionality in the signaling pathway, providing new hypotheses for future research. In addition, an increase in the number of proteins in the bradykinin signaling network will make this pathway linked to various new physiological events when future datasets subjected to gene set enrichment analyses.

Supplementary Information

Below is the link to the electronic supplementary material.

12079_2021_652_MOESM1_ESM.xlsx (85.7KB, xlsx)

A compendium of bradykinin-mediated signaling events. (XLSX 86 KB)

Acknowledgements

We acknowledge a research grant from Olav Thon Foundation entitled "Discovering new therapeutic targets and drugs to combat AMR tuberculosis: proteomics characterization and drug screening of mycobacterium-infected macrophages." We also thank Karnataka Biotechnology and Information Technology Services (KBITS), Government of Karnataka, for the support to the Center for Systems Biology and Molecular Medicine at Yenepoya (Deemed to be University) under the Biotechnology Skill Enhancement Programme in Multi-Omics Technology (BiSEP GO ITD 02 MDA 2017). RDAB is a recipient of a Senior Research Fellowship from the Indian Council of Medical Research (ICMR), Government of India.

Abbreviations

BK

Bradykinin

KKS

Kallikrein-kinin system

RAS

Renin-angiotensin system

B1R

Bradykinin receptor B1

B2R

Bradykinin receptor B2

PK

Plasma kallikrein

GPCR

G-protein coupled receptor

PIP2

Phosphatidylinositol 4, 5-bisphosphate

ACE

Angiotensin-converting enzyme

NO

Nitric oxide

PGI2

Prostaglandin I2

eNOS

Endothelial nitric oxide synthase

Declarations

Conflict of interest

The authors report no conflicts of interest.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

D. A. B. Rex, Email: rexprem@yenepoya.edu.in

K. Deepak, Email: newis27deepak@gmail.com

Neelanchal Vaid, Email: vneelanchal@gmail.com.

Shobha Dagamajalu, Email: shobha_d@yenepoya.edu.in.

Richard Kumaran Kandasamy, Email: richard.k.kandasamy@ntnu.no.

Trude Helen Flo, Email: trude.flo@ntnu.no.

T. S. Keshava Prasad, Email: keshav@yenepoya.edu.in

References

  1. Astuti I and Ysrafil (2020) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response. Diabetes Metab Syndr 14(4):407–412 [DOI] [PMC free article] [PubMed]
  2. Barnes PJ. Bradykinin and asthma. Thorax. 1992;47(11):979–983. doi: 10.1136/thx.47.11.979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G. Nonallergic angioedema: role of bradykinin. Allergy. 2007;62(8):842–856. doi: 10.1111/j.1398-9995.2007.01427.x. [DOI] [PubMed] [Google Scholar]
  4. Blaes N, Girolami JP. Targeting the 'Janus face' of the B2-bradykinin receptor. Expert Opin Ther Targets. 2013;17(10):1145–1166. doi: 10.1517/14728222.2013.827664. [DOI] [PubMed] [Google Scholar]
  5. Bossi F, Fischetti F, Regoli D, Durigutto P, Frossi B, Gobeil F, Jr, Ghebrehiwet B, Peerschke EI, Cicardi M, Tedesco F. Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. J Allergy Clin Immunol. 2009;124(6):1303–1310. doi: 10.1016/j.jaci.2009.08.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Campbell DJ, Alexiou T, Xiao HD, Fuchs S, McKinley MJ, Corvol P, Bernstein KE. Effect of reduced angiotensin-converting enzyme gene expression and angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptide levels in mice. Hypertension. 2004;43(4):854–859. doi: 10.1161/01.HYP.0000119190.06968.f1. [DOI] [PubMed] [Google Scholar]
  7. Chen BC, Yu CC, Lei HC, Chang MS, Hsu MJ, Huang CL, Chen MC, Sheu JR, Chen TF, Chen TL, Inoue H, Lin CH. Bradykinin B2 receptor mediates NF-kappaB activation and cyclooxygenase-2 expression via the Ras/Raf-1/ERK pathway in human airway epithelial cells. J Immunol. 2004;173(8):5219–5228. doi: 10.4049/jimmunol.173.8.5219. [DOI] [PubMed] [Google Scholar]
  8. Chu E, Saini S, Liu T, Yoo J. Bradykinin stimulates protein kinase D-mediated colonic myofibroblast migration via cyclooxygenase-2 and heat shock protein 27. J Surg Res. 2017;209:191–198. doi: 10.1016/j.jss.2016.10.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Clerk A, Gillespie-Brown J, Fuller SJ, Sugden PH. Stimulation of phosphatidylinositol hydrolysis, protein kinase C translocation, and mitogen-activated protein kinase activity by bradykinin in rat ventricular myocytes: dissociation from the hypertrophic response. Biochem J. 1996;317(Pt 1):109–118. doi: 10.1042/bj3170109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Couture R, Harrisson M, Vianna RM, Cloutier F. Kinin receptors in pain and inflammation. Eur J Pharmacol. 2001;429(1–3):161–176. doi: 10.1016/s0014-2999(01)01318-8. [DOI] [PubMed] [Google Scholar]
  11. da Costa PL, Sirois P, Tannock IF, Chammas R. The role of kinin receptors in cancer and therapeutic opportunities. Cancer Lett. 2014;345(1):27–38. doi: 10.1016/j.canlet.2013.12.009. [DOI] [PubMed] [Google Scholar]
  12. Dagamajalu S, Rex DAB, Gopalakrishnan L, Karthikkeyan G, Gurtoo S, Modi PK, Mohanty V, Mujeeburahiman M, Soman S, Raju R, Tiwari V, Prasad TSK. A network map of endothelin mediated signaling pathway. J Cell Commun Signal. 2021;15(2):277–282. doi: 10.1007/s12079-020-00581-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Dagamajalu S, Rex DAB, Palollathil A, Shetty R, Bhat G, Cheung LWT, Prasad TSK. A pathway map of AXL receptor-mediated signaling network. J Cell Commun Signal. 2021;15(1):143–148. doi: 10.1007/s12079-020-00580-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Dagnino APA, Campos MM, Silva RBM. Kinins and their receptors in infectious diseases. Pharmaceuticals (basel) 2020;13(9):215. doi: 10.3390/ph13090215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Davoine C, Bouckaert C, Fillet M, Pochet L. Factor XII/XIIa inhibitors: their discovery, development, and potential indications. Eur J Med Chem. 2020;208:112753. doi: 10.1016/j.ejmech.2020.112753. [DOI] [PubMed] [Google Scholar]
  16. Dey G, Radhakrishnan A, Syed N, Thomas JK, Nadig A, Srikumar K, Mathur PP, Pandey A, Lin SK, Raju R, Prasad TS. Signaling network of oncostatin M pathway. J Cell Commun Signal. 2013;7(2):103–108. doi: 10.1007/s12079-012-0186-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Dong R, Chen W, Feng W, Xia C, Hu D, Zhang Y, Yang Y, Wang DW, Xu X, Tu L. Exogenous bradykinin inhibits tissue factor induction and deep vein thrombosis via activating the eNOS/Phosphoinositide 3-Kinase/Akt signaling pathway. Cell Physiol Biochem. 2015;37(4):1592–1606. doi: 10.1159/000438526. [DOI] [PubMed] [Google Scholar]
  18. Drouin JN, St-Pierre SA, Regoli D. Receptors for bradykinin and kallidin. Can J Physiol Pharmacol. 1979;57(4):375–379. doi: 10.1139/y79-056. [DOI] [PubMed] [Google Scholar]
  19. Duchene J, Lecomte F, Ahmed S, Cayla C, Pesquero J, Bader M, Perretti M, Ahluwalia A. A novel inflammatory pathway involved in leukocyte recruitment: role for the kinin B1 receptor and the chemokine CXCL5. J Immunol. 2007;179(7):4849–4856. doi: 10.4049/jimmunol.179.7.4849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ehrenfeld P, Conejeros I, Pavicic MF, Matus CE, Gonzalez CB, Quest AF, Bhoola KD, Poblete MT, Burgos RA, Figueroa CD. Activation of kinin B1 receptor increases the release of metalloproteases-2 and -9 from both estrogen-sensitive and -insensitive breast cancer cells. Cancer Lett. 2011;301(1):106–118. doi: 10.1016/j.canlet.2010.09.020. [DOI] [PubMed] [Google Scholar]
  21. Falsetta ML, Foster DC, Woeller CF, Pollock SJ, Bonham AD, Haidaris CG, Phipps RP. A role for bradykinin signaling in chronic vulvar pain. J Pain. 2016;17(11):1183–1197. doi: 10.1016/j.jpain.2016.07.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Farkas H, Varga L. Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency. Clin Cosmet Investig Dermatol. 2011;4:61–68. doi: 10.2147/CCID.S10322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Fong D, Smith DI, Hsieh WT. The human kininogen gene (KNG) mapped to chromosome 3q26-qter by analysis of somatic cell hybrids using the polymerase chain reaction. Hum Genet. 1991;87(2):189–192. doi: 10.1007/BF00204179. [DOI] [PubMed] [Google Scholar]
  24. Garvin MR, Alvarez C, Miller JI, Prates ET, Walker AM, Amos BK, Mast AE, Justice A, Aronow B, Jacobson D (2020) A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife 9:e59177. 10.7554/eLife.59177 [DOI] [PMC free article] [PubMed]
  25. Graness A, Adomeit A, Ludwig B, Muller WD, Kaufmann R, Liebmann C. Novel bradykinin signalling events in PC-12 cells: stimulation of the cAMP pathway leads to cAMP-mediated translocation of protein kinase Cepsilon. Biochem J. 1997;327(Pt 1):147–154. doi: 10.1042/bj3270147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Graness A, Adomeit A, Heinze R, Wetzker R, Liebmann C. A novel mitogenic signaling pathway of bradykinin in the human colon carcinoma cell line SW-480 involves sequential activation of a Gq/11 protein phosphatidylinositol 3-kinase β and protein kinase Cε. J Biol Chem. 1998;273(48):32016–32022. doi: 10.1074/jbc.273.48.32016. [DOI] [PubMed] [Google Scholar]
  27. Greco S, Muscella A, Elia MG, Romano S, Storelli C, Marsigliante S. Mitogenic signalling by B2 bradykinin receptor in epithelial breast cells. J Cell Physiol. 2004;201(1):84–96. doi: 10.1002/jcp.20052. [DOI] [PubMed] [Google Scholar]
  28. Greco S, Elia MG, Muscella A, Romano S, Storelli C, Marsigliante S. Bradykinin stimulates cell proliferation through an extracellular-regulated kinase 1 and 2-dependent mechanism in breast cancer cells in primary culture. J Endocrinol. 2005;186(2):291–301. doi: 10.1677/joe.1.06052. [DOI] [PubMed] [Google Scholar]
  29. Greco S, Storelli C, Marsigliante S. Protein kinase C (PKC)-delta/-epsilon mediate the PKC/Akt-dependent phosphorylation of extracellular signal-regulated kinases 1 and 2 in MCF-7 cells stimulated by bradykinin. J Endocrinol. 2006;188(1):79–89. doi: 10.1677/joe.1.06433. [DOI] [PubMed] [Google Scholar]
  30. Hofman Z, de Maat S, Hack CE, Maas C. Bradykinin: inflammatory product of the coagulation system. Clin Rev Allergy Immunol. 2016;51(2):152–161. doi: 10.1007/s12016-016-8540-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Hofman ZL, Relan A, Zeerleder S, Drouet C, Zuraw B, Hack CE. Angioedema attacks in patients with hereditary angioedema: local manifestations of a systemic activation process. J Allergy Clin Immunol. 2016;138(2):359–366. doi: 10.1016/j.jaci.2016.02.041. [DOI] [PubMed] [Google Scholar]
  32. Hsieh HL, Wang HH, Wu CY, Jou MJ, Yen MH, Parker P, Yang CM. BK-induced COX-2 expression via PKC-delta-dependent activation of p42/p44 MAPK and NF-kappaB in astrocytes. Cell Signal. 2007;19(2):330–340. doi: 10.1016/j.cellsig.2006.07.006. [DOI] [PubMed] [Google Scholar]
  33. Huang CD, Tliba O, Panettieri RA, Jr, Amrani Y. Bradykinin induces interleukin-6 production in human airway smooth muscle cells: modulation by Th2 cytokines and dexamethasone. Am J Respir Cell Mol Biol. 2003;28(3):330–338. doi: 10.1165/rcmb.2002-0040OC. [DOI] [PubMed] [Google Scholar]
  34. Izumi S, Higa-Nakamine S, Nishi H, Torihara H, Uehara A, Sugahara K, Kakinohana M, Yamamoto H. Phosphorylation of epidermal growth factor receptor at serine 1047 in cultured lung alveolar epithelial cells by bradykinin B2 receptor stimulation. Pulm Pharmacol Ther. 2018;48:53–61. doi: 10.1016/j.pupt.2017.09.002. [DOI] [PubMed] [Google Scholar]
  35. Jaffa MA, Kobeissy F, Al Hariri M, Chalhoub H, Eid A, Ziyadeh FN, Jaffa AA. Global renal gene expression profiling analysis in B2-kinin receptor null mice: impact of diabetes. PLoS ONE. 2012;7(9):e44714. doi: 10.1371/journal.pone.0044714. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Jalowy A, Schulz R, Dorge H, Behrends M, Heusch G. Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol. 1998;32(6):1787–1796. doi: 10.1016/s0735-1097(98)00441-0. [DOI] [PubMed] [Google Scholar]
  37. Kakoki M, Smithies O. The kallikrein-kinin system in health and in diseases of the kidney. Kidney Int. 2009;75(10):1019–1030. doi: 10.1038/ki.2008.647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Kandasamy K, Keerthikumar S, Raju R, Keshava Prasad TS, Ramachandra YL, Mohan S, Pandey A. PathBuilder–open source software for annotating and developing pathway resources. Bioinformatics. 2009;25(21):2860–2862. doi: 10.1093/bioinformatics/btp453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Kandasamy K, Mohan SS, Raju R, Keerthikumar S, Kumar GS, Venugopal AK, Telikicherla D, Navarro JD, Mathivanan S, Pecquet C, Gollapudi SK, Tattikota SG, Mohan S, Padhukasahasram H, Subbannayya Y, Goel R, Jacob HK, Zhong J, Sekhar R, Nanjappa V, Balakrishnan L, Subbaiah R, Ramachandra YL, Rahiman BA, Prasad TS, Lin JX, Houtman JC, Desiderio S, Renauld JC, Constantinescu SN, Ohara O, Hirano T, Kubo M, Singh S, Khatri P, Draghici S, Bader GD, Sander C, Leonard WJ, Pandey A. NetPath: a public resource of curated signal transduction pathways. Genome Biol. 2010;11(1):R3. doi: 10.1186/gb-2010-11-1-r3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Kaplan AP, Joseph K, Silverberg M. Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol. 2002;109(2):195–209. doi: 10.1067/mai.2002.121316. [DOI] [PubMed] [Google Scholar]
  41. Kenniston JA, Faucette RR, Martik D, Comeau SR, Lindberg AP, Kopacz KJ, Conley GP, Chen J, Viswanathan M, Kastrapeli N, Cosic J, Mason S, DiLeo M, Abendroth J, Kuzmic P, Ladner RC, Edwards TE, TenHoor C, Adelman BA, Nixon AE, Sexton DJ. Inhibition of plasma kallikrein by a highly specific active site blocking antibody. J Biol Chem. 2014;289(34):23596–23608. doi: 10.1074/jbc.M114.569061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Khasar SG, Miao FJ, Levine JD. Inflammation modulates the contribution of receptor-subtypes to bradykinin-induced hyperalgesia in the rat. Neuroscience. 1995;69(2):685–690. doi: 10.1016/0306-4522(95)00280-v. [DOI] [PubMed] [Google Scholar]
  43. Kmietowicz Z. ACE inhibitors are linked to increased lung cancer risk, study finds. BMJ. 2018;363:k4471. doi: 10.1136/bmj.k4471. [DOI] [PubMed] [Google Scholar]
  44. Kramarenko II, Morinelli TA, Bunni MA, Raymond JR, Sr, Garnovskaya MN. The bradykinin B(2) receptor induces multiple cellular responses leading to the proliferation of human renal carcinoma cell lines. Cancer Manag Res. 2012;4:195–205. doi: 10.2147/CMAR.S31847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Krankel N, Katare RG, Siragusa M, Barcelos LS, Campagnolo P, Mangialardi G, Fortunato O, Spinetti G, Tran N, Zacharowski K, Wojakowski W, Mroz I, Herman A, Manning Fox JE, MacDonald PE, Schanstra JP, Bascands JL, Ascione R, Angelini G, Emanueli C, Madeddu P. Role of kinin B2 receptor signaling in the recruitment of circulating progenitor cells with neovascularization potential. Circ Res. 2008;103(11):1335–1343. doi: 10.1161/CIRCRESAHA.108.179952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Kutmon M, van Iersel MP, Bohler A, Kelder T, Nunes N, Pico AR, Evelo CT. PathVisio 3: an extendable pathway analysis toolbox. PLoS Comput Biol. 2015;11(2):e1004085. doi: 10.1371/journal.pcbi.1004085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Lau J, Rousseau J, Kwon D, Benard F, Lin KS. A systematic review of molecular imaging agents targeting bradykinin B1 and B2 receptors. Pharmaceuticals (basel) 2020;13(8):199. doi: 10.3390/ph13080199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Lee CH, Shieh DC, Tzeng CY, Chen CP, Wang SP, Chiu YC, Huang CY, Hsu CJ, Fong YC, Tang CH. Bradykinin-induced IL-6 expression through bradykinin B2 receptor, phospholipase C, protein kinase Cdelta and NF-kappaB pathway in human synovial fibroblasts. Mol Immunol. 2008;45(14):3693–3702. doi: 10.1016/j.molimm.2008.06.007. [DOI] [PubMed] [Google Scholar]
  49. Lee K, Kim YJ, Choi LM, Choi S, Nam H, Ko HY, Chung G, Lee JH, Jo SH, Lee G, Choi SY, Park K. Human salivary gland cells express bradykinin receptors that modulate the expression of proinflammatory cytokines. Eur J Oral Sci. 2017;125(1):18–27. doi: 10.1111/eos.12324. [DOI] [PubMed] [Google Scholar]
  50. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev. 2005;57(1):27–77. doi: 10.1124/pr.57.1.2. [DOI] [PubMed] [Google Scholar]
  51. Lesage A, Gibson C, Marceau F, Ambrosi HD, Saupe J, Katzer W, Loenders B, Charest-Morin X, Knolle J. In vitro pharmacological profile of a new small molecule bradykinin B2 receptor antagonist. Front Pharmacol. 2020;11:916. doi: 10.3389/fphar.2020.00916. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Li G, Wang Y, Li GR. Bradykinin regulates cell growth and migration in cultured human cardiac c-Kit+ progenitor cells. Oncotarget. 2017;8(7):10822–10835. doi: 10.18632/oncotarget.14609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Li G, Che H, Wu WY, Jie LJ, Xiao GS, Wang Y, Li GR. Bradykinin-mediated Ca(2+) signalling regulates cell growth and mobility in human cardiac c-Kit(+) progenitor cells. J Cell Mol Med. 2018;22(10):4688–4699. doi: 10.1111/jcmm.13706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Lim SK, Park MJ, Jung HK, Park AY, Kim DI, Kim JC, Bae CS, Kim KY, Yoon KC, Han HJ, Park SH. Bradykinin stimulates glutamate uptake via both B1R and B2R activation in a human retinal pigment epithelial cells. Life Sci. 2008;83(23–24):761–770. doi: 10.1016/j.lfs.2008.09.014. [DOI] [PubMed] [Google Scholar]
  55. Manning ME, Kashkin JM. Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies. Allergy Asthma Proc. 2021;42(4):274–282. doi: 10.2500/aap.2021.42.210034. [DOI] [PubMed] [Google Scholar]
  56. Marceau F, Sabourin T, Houle S, Fortin JP, Petitclerc E, Molinaro G, Adam A. Kinin receptors: functional aspects. Int Immunopharmacol. 2002;2(13–14):1729–1739. doi: 10.1016/s1567-5769(02)00189-3. [DOI] [PubMed] [Google Scholar]
  57. Marceau F, Bachelard H, Bouthillier J, Fortin JP, Morissette G, Bawolak MT, Charest-Morin X, Gera L. Bradykinin receptors: agonists, antagonists, expression, signaling, and adaptation to sustained stimulation. Int Immunopharmacol. 2020;82:106305. doi: 10.1016/j.intimp.2020.106305. [DOI] [PubMed] [Google Scholar]
  58. Meini S, Cucchi P, Catalani C, Bellucci F, Giuliani S, Maggi CA. Bradykinin and B(2) receptor antagonism in rat and human articular chondrocytes. Br J Pharmacol. 2011;162(3):611–622. doi: 10.1111/j.1476-5381.2010.01062.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Moraes MS, Costa PE, Batista WL, Paschoalin T, Curcio MF, Borges RE, Taha MO, Fonseca FV, Stern A, Monteiro HP. Endothelium-derived nitric oxide (NO) activates the NO-epidermal growth factor receptor-mediated signaling pathway in bradykinin-stimulated angiogenesis. Arch Biochem Biophys. 2014;558:14–27. doi: 10.1016/j.abb.2014.06.011. [DOI] [PubMed] [Google Scholar]
  60. Motta Junior JDS, Miggiolaro A, Nagashima S, de Paula CBV, Baena CP, Scharfstein J, de Noronha L. Mast cells in alveolar septa of COVID-19 patients: a pathogenic pathway that may link interstitial edema to immunothrombosis. Front Immunol. 2020;11:574862. doi: 10.3389/fimmu.2020.574862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Naffah-Mazzacoratti Mda G, Gouveia TL, Simoes PS, Perosa SR. What have we learned about the kallikrein-kinin and renin-angiotensin systems in neurological disorders? World J Biol Chem. 2014;5(2):130–140. doi: 10.4331/wjbc.v5.i2.130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Nokkari A, Abou-El-Hassan H, Mechref Y, Mondello S, Kindy MS, Jaffa AA, Kobeissy F. Implication of the Kallikrein–Kinin system in neurological disorders: quest for potential biomarkers and mechanisms. Prog Neurobiol. 2018;165–167:26–50. doi: 10.1016/j.pneurobio.2018.01.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Paegelow I, Werner H, Vietinghoff G, Wartner U. Release of cytokines from isolated lung strips by bradykinin. Inflamm Res. 1995;44(7):306–311. doi: 10.1007/BF02032574. [DOI] [PubMed] [Google Scholar]
  64. Pan ZK, Zuraw BL, Lung CC, Prossnitz ER, Browning DD, Ye RD. Bradykinin stimulates NF-kappaB activation and interleukin 1beta gene expression in cultured human fibroblasts. J Clin Invest. 1996;98(9):2042–2049. doi: 10.1172/JCI119009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Pinto SM, Subbannayya Y, Rex DAB, Raju R, Chatterjee O, Advani J, Radhakrishnan A, Keshava Prasad TS, Wani MR, Pandey A. A network map of IL-33 signaling pathway. J Cell Commun Signal. 2018;12(3):615–624. doi: 10.1007/s12079-018-0464-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Qadri F, Bader M. Kinin B1 receptors as a therapeutic target for inflammation. Expert Opin Ther Targets. 2018;22(1):31–44. doi: 10.1080/14728222.2018.1409724. [DOI] [PubMed] [Google Scholar]
  67. Raju R, Nanjappa V, Balakrishnan L, Radhakrishnan A, Thomas JK, Sharma J, Tian M, Palapetta SM, Subbannayya T, Sekhar NR, Muthusamy B, Goel R, Subbannayya Y, Telikicherla D, Bhattacharjee M, Pinto SM, Syed N, Srikanth MS, Sathe GJ, Ahmad S, Chavan SN, Kumar GS, Marimuthu A, Prasad TS, Harsha HC, Rahiman BA, Ohara O, Bader GD, Sujatha Mohan S, Schiemann WP, Pandey A. NetSlim: high-confidence curated signaling maps. Database (oxford) 2011;2011:bae032. doi: 10.1093/database/bar032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Rex DAB, Agarwal N, Prasad TSK, Kandasamy RK, Subbannayya Y, Pinto SM. A comprehensive pathway map of IL-18-mediated signalling. J Cell Commun Signal. 2020;14(2):257–266. doi: 10.1007/s12079-019-00544-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Rex DAB, Dagamajalu S, Kandasamy RK, Raju R, and Prasad, TSK (2021) SARS-CoV-2 signaling pathway map: A functional landscape of molecular mechanisms in COVID-19. J Cell Commun Signal [DOI] [PMC free article] [PubMed]
  70. Ricciardolo FLM, Folkerts G, Folino A, Mognetti B. Bradykinin in asthma: modulation of airway inflammation and remodelling. Eur J Pharmacol. 2018;827:181–188. doi: 10.1016/j.ejphar.2018.03.017. [DOI] [PubMed] [Google Scholar]
  71. Roche JA, Roche R. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications. FASEB J. 2020;34(6):7265–7269. doi: 10.1096/fj.202000967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Sancho-Bru P, Bataller R, Fernandez-Varo G, Moreno M, Ramalho LN, Colmenero J, Mari M, Claria J, Jimenez W, Arroyo V, Brenner DA, Gines P. Bradykinin attenuates hepatocellular damage and fibrosis in rats with chronic liver injury. Gastroenterology. 2007;133(6):2019–2028. doi: 10.1053/j.gastro.2007.09.023. [DOI] [PubMed] [Google Scholar]
  73. Saoud R, Jaffa MA, Habib A, Zhao J, Al Hariri M, Zhu R, Hasan A, Ziyadeh FN, Kobeissy F, Mechref Y, Jaffa AA. Modulation of proteomic and inflammatory signals by Bradykinin in podocytes. J Adv Res. 2020;24:409–422. doi: 10.1016/j.jare.2020.05.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Sharif NA, Xu S, Li L, Katoli P, Kelly CR, Wang Y, Cao S, Patil R, Husain S, Klekar L, Scott D. Protein expression, biochemical pharmacology of signal transduction, and relation to intraocular pressure modulation by bradykinin B(2) receptors in ciliary muscle. Mol vis. 2013;19:1356–1370. [PMC free article] [PubMed] [Google Scholar]
  75. Singh PK, Chen ZL, Ghosh D, Strickland S, Norris EH. Increased plasma bradykinin level is associated with cognitive impairment in Alzheimer's patients. Neurobiol Dis. 2020;139:104833. doi: 10.1016/j.nbd.2020.104833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Singh PK, Chen ZL, Strickland S, Norris EH. Increased contact system activation in mild cognitive impairment patients with impaired short-term memory. J Alzheimers Dis. 2020;77(1):59–65. doi: 10.3233/JAD-200343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Soman S, Raju R, Sandhya VK, Advani J, Khan AA, Harsha HC, Prasad TS, Sudhakaran PR, Pandey A, Adishesha PK. A multicellular signal transduction network of AGE/RAGE signaling. J Cell Commun Signal. 2013;7(1):19–23. doi: 10.1007/s12079-012-0181-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Stewart JM, Gera L, Chan DC, Bunn PA, Jr, York EJ, Simkeviciene V, Helfrich B. Bradykinin-related compounds as new drugs for cancer and inflammation. Can J Physiol Pharmacol. 2002;80(4):275–280. doi: 10.1139/y02-030. [DOI] [PubMed] [Google Scholar]
  79. Tan Y, Wang B, Keum JS, Jaffa AA. Mechanisms through which bradykinin promotes glomerular injury in diabetes. Am J Physiol Renal Physiol. 2005;288(3):F483–F492. doi: 10.1152/ajprenal.00165.2004. [DOI] [PubMed] [Google Scholar]
  80. Tanabe A, Shiraishi M, Negishi M, Saito N, Tanabe M, Sasaki Y. MARCKS dephosphorylation is involved in bradykinin-induced neurite outgrowth in neuroblastoma SH-SY5Y cells. J Cell Physiol. 2012;227(2):618–629. doi: 10.1002/jcp.22763. [DOI] [PubMed] [Google Scholar]
  81. Terzuoli E, Corti F, Nannelli G, Giachetti A, Donnini S, Ziche M. Bradykinin B2 receptor contributes to inflammatory responses in human endothelial cells by the transactivation of the fibroblast growth factor receptor FGFR-1. Int J Mol Sci. 2018;19(9):2638. doi: 10.3390/ijms19092638. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Tschope C, Schultheiss HP, Walther T. Multiple interactions between the renin-angiotensin and the kallikrein-kinin systems: role of ACE inhibition and AT1 receptor blockade. J Cardiovasc Pharmacol. 2002;39(4):478–487. doi: 10.1097/00005344-200204000-00003. [DOI] [PubMed] [Google Scholar]
  83. Vandell AG, Larson N, Laxmikanthan G, Panos M, Blaber SI, Blaber M, Scarisbrick IA. Protease-activated receptor dependent and independent signaling by kallikreins 1 and 6 in CNS neuron and astroglial cell lines. J Neurochem. 2008;107(3):855–870. doi: 10.1111/j.1471-4159.2008.05658.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Verma R, Balakrishnan L, Sharma K, Khan AA, Advani J, Gowda H, Tripathy SP, Suar M, Pandey A, Gandotra S, Prasad TS, Shankar S. A network map of Interleukin-10 signaling pathway. J Cell Commun Signal. 2016;10(1):61–67. doi: 10.1007/s12079-015-0302-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Virych PA, Shelyuk OV, Kabanova TA, Khalimova EI, Martynyuk VS, Pavlovsky VI, Andronati SA. Effect of 3-substituted 1,4-benzodiazepin-2-ones on bradykinin-induced smooth muscle contraction. Ukr Biochem J. 2017;89(1):31–37. doi: 10.15407/ubj89.01.031. [DOI] [PubMed] [Google Scholar]
  86. Wang S, Dai Y, Fukuoka T, Yamanaka H, Kobayashi K, Obata K, Cui X, Tominaga M, Noguchi K. Phospholipase C and protein kinase A mediate bradykinin sensitization of TRPA1: a molecular mechanism of inflammatory pain. Brain. 2008;131(Pt 5):1241–1251. doi: 10.1093/brain/awn060. [DOI] [PubMed] [Google Scholar]
  87. Wang G, Ye Y, Zhang X, Song J. Bradykinin stimulates IL-6 production and cell invasion in colorectal cancer cells. Oncol Rep. 2014;32(4):1709–1714. doi: 10.3892/or.2014.3366. [DOI] [PubMed] [Google Scholar]
  88. Wang G, Sun J, Liu G, Fu Y, Zhang X. Bradykinin promotes cell proliferation, migration, invasion, and tumor growth of gastric cancer through ERK signaling pathway. J Cell Biochem. 2017;118(12):4444–4453. doi: 10.1002/jcb.26100. [DOI] [PubMed] [Google Scholar]
  89. Wang W, Zhou Y, Wei R, Jiang G, Li Fei, Chen Xi, Wang Xueqian, Ma Ding, Xi Ling. Bradykinin promotes proliferation migration and invasion of cervical cancer cells through STAT3 signaling pathways. Oncol Rep. 2019 doi: 10.3892/or.2019.7380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Webb JG, Yang X, Crosson CE. Bradykinin activation of extracellular signal-regulated kinases in human trabecular meshwork cells. Exp Eye Res. 2011;92(6):495–501. doi: 10.1016/j.exer.2011.03.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Wedner HJ, Aygoren-Pursun E, Bernstein J, Craig T, Gower R, Jacobs JS, Johnston DT, Lumry WR, Zuraw BL, Best JM, Iocca HA, Murray SC, Desai B, Nagy E, Sheridan WP, Kiani-Alikhan S. Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (Part 2) J Allergy Clin Immunol Pract. 2021;9(6):2305–2314e4. doi: 10.1016/j.jaip.2021.03.057. [DOI] [PubMed] [Google Scholar]
  92. Whalley ET, Figueroa CD, Gera L, Bhoola KD. Discovery and therapeutic potential of kinin receptor antagonists. Expert Opin Drug Discov. 2012;7(12):1129–1148. doi: 10.1517/17460441.2012.729038. [DOI] [PubMed] [Google Scholar]
  93. Wilczynski SA, Wenceslau CF, McCarthy CG, Webb RC. A cytokine/bradykinin storm comparison: What is the relationship between hypertension and COVID-19? Am J Hypertens. 2021;34(4):304–306. doi: 10.1093/ajh/hpaa217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Wirth K, Hock FJ, Albus U, Linz W, Alpermann HG, Anagnostopoulos H, Henk S, Breipohl G, Konig W, Knolle J, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol. 1991;102(3):774–777. doi: 10.1111/j.1476-5381.1991.tb12249.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Xie P, Browning DD, Hay N, Mackman N, Ye RD. Activation of NF-κB by bradykinin through a Gαq- and Gβγ-dependent pathway that involves phosphoinositide 3-kinase and Akt. J Biol Chem. 2000;275(32):24907–24914. doi: 10.1074/jbc.M001051200. [DOI] [PubMed] [Google Scholar]
  96. Yang W-H, Chang J-T, Hsu S-F, Li T-M, Cho D-Y, Huang C-Y, Fong Y-C, Tang C-H. Bradykinin enhances cell migration in human chondrosarcoma cells through BK receptor signaling pathways. J Cell Biochem. 2009 doi: 10.1002/jcb.22383. [DOI] [PubMed] [Google Scholar]
  97. Yang L, Zhang J, Li N, Xie H, Chen S, Wang H, Shen T, Zhu QX. Bradykinin receptor in immune-mediated renal tubular injury in trichloroethylene-sensitized mice: impact on NF-kappaB signaling pathway. J Immunotoxicol. 2018;15(1):126–136. doi: 10.1080/1547691X.2018.1532974. [DOI] [PubMed] [Google Scholar]
  98. Yu HS, Lin TH, Tang CH. Bradykinin enhances cell migration in human prostate cancer cells through B2 receptor/PKCdelta/c-Src dependent signaling pathway. Prostate. 2013;73(1):89–100. doi: 10.1002/pros.22544. [DOI] [PubMed] [Google Scholar]
  99. Yu HS, Wang SW, Chang AC, Tai HC, Yeh HI, Lin YM, Tang CH. Bradykinin promotes vascular endothelial growth factor expression and increases angiogenesis in human prostate cancer cells. Biochem Pharmacol. 2014;87(2):243–253. doi: 10.1016/j.bcp.2013.10.016. [DOI] [PubMed] [Google Scholar]
  100. Zhang W, Bhola N, Kalyankrishna S, Gooding W, Hunt J, Seethala R, Grandis JR, Siegfried JM. Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas. Mol Cancer Res. 2008;6(12):1946–1956. doi: 10.1158/1541-7786.MCR-07-2197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–590. doi: 10.1007/s00134-020-05985-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Zhu YM, Bradbury DA, Pang L, Knox AJ. Transcriptional regulation of interleukin (IL)-8 by bradykinin in human airway smooth muscle cells involves prostanoid-dependent activation of AP-1 and nuclear factor (NF)-IL-6 and prostanoid-independent activation of NF-kappaB. J Biol Chem. 2003;278(31):29366–29375. doi: 10.1074/jbc.M301785200. [DOI] [PubMed] [Google Scholar]
  103. Zhu L, Carretero OA, Liao TD, Harding P, Li H, Sumners C, Yang XP. Role of prolylcarboxypeptidase in angiotensin II type 2 receptor-mediated bradykinin release in mouse coronary artery endothelial cells. Hypertension. 2010;56(3):384–390. doi: 10.1161/HYPERTENSIONAHA.110.155051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Zuraw B, Lumry WR, Johnston DT, Aygoren-Pursun E, Banerji A, Bernstein JA, Christiansen SC, Jacobs JS, Sitz KV, Gower RG, Gagnon R, Wedner HJ, Kinaciyan T, Hakl R, Hanzlikova J, Anderson JT, McNeil DL, Fritz SB, Yang WH, Tachdjian R, Busse PJ, Craig TJ, Li HH, Farkas H, Best JM, Clemons D, Cornpropst M, Dobo SM, Iocca HA, Kargl D, Nagy E, Murray SC, Collis P, Sheridan WP, Maurer M, Riedl MA. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. J Allergy Clin Immunol. 2021;148(1):164–1729. doi: 10.1016/j.jaci.2020.10.015. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

12079_2021_652_MOESM1_ESM.xlsx (85.7KB, xlsx)

A compendium of bradykinin-mediated signaling events. (XLSX 86 KB)

Articles from Journal of Cell Communication and Signaling are provided here courtesy of The International CCN Society

RESOURCES